Taniguchi Daisuke, Ahmadipour Mohammadali, Eiliazadeh Anthony L, Duchesneau Pascal, Nagayasu Takeshi, Haykal Siba, Karoubi Golnaz, Waddell Thomas K
Latner Thoracic Research Laboratories, DIvision of Thoracic Surgery, 101 College St. 2-817, Toronto, ON, M5G1L7, Canada.
Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Regen Ther. 2023 Dec 20;25:92-100. doi: 10.1016/j.reth.2023.11.011. eCollection 2024 Mar.
Tissue engineering approaches via repopulation of acellular biological grafts provide an exciting opportunity to generate lung grafts for transplantation. Alveolar type 2 (AT2) cells are a promising cell source for re-epithelialization. There are however inherent limitations with respect to their survival and growth, thus impeding their usability for tissue engineering applications. This study investigates the use of mesenchymal stromal cells to support primary AT2 cells for recellularization of mouse lung scaffolds.
AT2 cells and bone marrow-derived mesenchymal cells (BMC) were co-delivered to decellularized mouse lung scaffolds. Recellularized lungs were evaluated for cell surface coverage, viability, and differentiation at 1 and 4 days after cell seeding. Recellularization was evaluated via histological analysis and immunofluorescence.
Simultaneous delivery of AT2 and BMC into acellular lung scaffolds resulted in enhanced cell surface coverage and reduced AT2 cell apoptosis in the recellularized scaffolds at Day 1 but not Day 4. AT2 cell number decreased after 4 days in both of AT2 only and codelivery groups suggesting limited expansion potential in the scaffold. After retention in the scaffold, AT2 cells differentiated into Aqp5-expressing cells.
Our results indicate that BMC support AT2 cell survival during the initial attachment and engraftment phase of recellularization. While our findings suggest only a short-term beneficial effect of BMC, our study demonstrates that AT2 cells can be delivered and retained in acellular lung scaffolds; thus with preconditioning and supporting cells, may be used for re-epithelialization. Selection and characterization of appropriate cell sources for use in recellularization, will be critical for ultimate clinical application.
通过无细胞生物移植物重新填充的组织工程方法为生成用于移植的肺移植物提供了一个令人兴奋的机会。2型肺泡(AT2)细胞是用于重新上皮化的有前景的细胞来源。然而,它们的存活和生长存在固有限制,从而阻碍了它们在组织工程应用中的可用性。本研究调查了间充质基质细胞用于支持原代AT2细胞对小鼠肺支架进行再细胞化的用途。
将AT2细胞和骨髓来源的间充质细胞(BMC)共同递送至脱细胞的小鼠肺支架。在细胞接种后1天和4天,对再细胞化的肺进行细胞表面覆盖、活力和分化评估。通过组织学分析和免疫荧光评估再细胞化情况。
在第1天而非第4天,将AT2细胞和BMC同时递送至无细胞肺支架导致再细胞化支架中的细胞表面覆盖增强且AT2细胞凋亡减少。在仅AT2细胞组和共同递送组中,4天后AT2细胞数量均减少,表明支架中的扩增潜力有限。在支架中留存后,AT2细胞分化为表达水通道蛋白5(Aqp5)的细胞。
我们的结果表明,在再细胞化的初始附着和植入阶段,BMC支持AT2细胞存活。虽然我们的研究结果仅表明BMC具有短期有益作用,但我们的研究证明AT2细胞可以递送至无细胞肺支架并在其中留存;因此,通过预处理和支持细胞,可用于重新上皮化。选择和鉴定用于再细胞化的合适细胞来源对于最终的临床应用至关重要。